Arena: Considerable side effects of chemoembolization for colorectal carcinoma metastatic to the liver

20Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Summary: The feasibility of one whole liver chemoembolization (CE) procedure with Angjostat, a vasoocclusive collagen, mitomycin, doxorubicin, and cisplatin was evaluated in eight patients with unresectable colorectal carcinoma metastatic to the liver and good performance status. One heavily pretreated patient showed a partial response in the liver lasting 188 days. Five patients had stabilization of the disease for 85-150 days. The side effects of the treatment were considerable with a fatigue syndrome lasting up to eight weeks, chemical and ischemic hepatitis, severe thrombopenia (WHO grade 4 in 2 pts) and icterus being the most disturbing toxicities. We recommend to restrict CE to patients with a life expectancy of more than 4-6 months confined to protocols, which evaluate efficacy, toxicity and influence on quality of life of CE with various cytotoxic drugs. We further suggest to perform staged unilobar CE at 4- to 6-week intervals rather than whole liver CE. © 1992 Kluwer Academic Publishers.

Cite

CITATION STYLE

APA

Borner, M., Castiglione, M., Triller, J., Baer, H. U., Soucek, M., Blumgart, L., & Brunner, K. (1992). Arena: Considerable side effects of chemoembolization for colorectal carcinoma metastatic to the liver. Annals of Oncology, 3(2), 113–115. https://doi.org/10.1093/oxfordjournals.annonc.a058123

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free